Chemotherapy side effects and their management

Supportive Care in Cancer: A Handbook for Oncologists

Volumn , Issue , 1999, Pages 279-295

  Klener, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141625509     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19:529-542.
2. Carlson RW. Reducing the cardiotoxicity of anthracyclines. Oncology 1992; 6:95-100.
3. Hochter H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995; 7:304-309.
4. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133-139.
5. Matsuda A, Kimura M, Itokawa Y. Influence of selenium deficiency on the acute cardiotoxicity of adriamycin in rats. Biol Trace Elem Res 1997; 57:157-167.
6. Sadzuka Y, Sugiyama T, Shimoi K, et al. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 1997; 92:1-7.
7. Monti E, Cova D, Guido E, et al. Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med 1996; 21:463-470.
8. Kim C, Nam SW, Choi DY, et al. A new antithrombotic agent, aspalatone, attenuated cardiotoxicity induced by doxorubicin in the mouse. Life Sci 1997; 60:75-82.
9. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992; 19:506-520.
10. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80:1134-1140.
11. Weinstein AS, Diener-West M, Nelson DF, et al. Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep 1986; 70:943-946.
12. Lehne G, Lote K. Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review. Acta Oncol 1990; 29:113-124.
13. Anderson BS, Cogan BM, Keating MJ, et al. Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukemia. Cancer 1985; 56:2181-2184.
14. Deterding RR, Havill AM, Yano T, et al. Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Phys 1997; 109:254-268.
15. Takeoka M, Ward WF, Pollack H, et al. KGF facilitated repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol 1997; 272:1174-1180.
16. Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiationand bleomycin-induced lung injury and mortality. Am J Pathol 1996; 149:1963-1970.
17. Gurujeyalaksmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis. Exp Lung Res 1995; 21: 791-808.
18. Kilinic C, Ozcan O, Karaoz E, et al. Vitamin E reduces bleomycin-induced lung fibrosis in mice. J Basic Clin Physiol Pharmacol 1993; 4:249-269.
19. Nagler A, Firman N, Feferman R, et al. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996; 154:1082-1086.
20. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21:33-64.
21. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992; 19:521-528.
22. Perry MC, ed. Toxicity of chemotherapy. Baltimore, Williams & Wilkins, 1992.
23. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11:1813-1816.
24. McCauley DL. Amifostine. A novel cytoprotective agent. Cancer Pract 1997; 5: 189-191.
25. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities. J Clin Oncol 1996; 14: 2101-2112.
26. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer. J Clin Oncol 1996; 14:1913-1921.
27. Spencer CM, Goa KL. Amifostine. Drugs 1995; 50:1001-1031.
28. Vogelzang NJ. Nephrotoxicity from chemotherapy. Prevention and management. Oncology 1991; 5:97-105.
29. Derry JM, Jacobs C, Sikio B, et al. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990; 8:1585-1590.
30. Kaplan RS, Wiernik P. Neurotoxicity of antineoplastic drugs. Semin Oncol 1982; 9:103-130.
31. Roberts JA, Jenison EL, Kim K, et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol. Oncol. 67, 1977, p. 172-177.
32. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322:126.
33. Curtin JP, Koonigs PP, Guttirez M, et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991; 42:193-197.
34. Apfel SC, Lipton RB, Arezzo JC, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29:87-91.
35. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide. Eur J Clin Pharmacol 1996; 50:249-252.
36. Alonso JL, Nieto Y, Lopez JA, et al: Ifosfamide encephalopathy and methyleneblue: A case report. Ann Oncol 1996; 7:643-44.